ALXO | tickerfilter.com

Fundamental analysis

42%

Profitability 35%

Dept financing 27%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.80%

1 Month

-14.14%

3 Months

4.46%

6 Months

3.14%

1 Year

221.57%

2 Year

-90.31%

Key data

Stock price

$1.64

P/E Ratio

N/A

DAY RANGE

$1.55 - $1.66

EPS

-$1.94

52 WEEK RANGE

$0.40 - $2.66

52 WEEK CHANGE

$203.70

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

131.608 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

0.56

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,423,722

AVERAGE 30 VOLUME

$1,221,040

Company detail

CEO: Jaume Pons
Region: US
Website: alxoncology.com
Employees: 40
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ALX Oncology Holdings Inc. focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial. ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

ALXO - ALX ONCOLOGY HOLDINGS INC